Augmedix, Inc.
AUGXNASDAQHealthcare
$2.35
$-0.01(-0.21%)
Market Cap$115908895
P/E Ratio—
52W High$6.25
52W Low$0.73
Augmedix, Inc. (AUGX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AUGX · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2024Report Date: Nov 4, 2024EPS Actual
-$0.10
Est. -$0.15 · +33.3%
Revenue
—
Est. $0.01B
Fiscal Period
Q4 FY2024
FY ends December
Report Date
Nov 4, 2024
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
AUGX reports quarterly as a NASDAQ-listed Medical - Healthcare Information Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2024 | Nov 4, 2024 | -$0.15 | -$0.10 | +33.3% | — | $0.01B | — |
| ▼ Q3 FY2024 | Aug 12, 2024 | -$0.12 | -$0.16 | -33.3% | $0.01B | $0.01B | +0.2% |
| — Q2 FY2024 | May 13, 2024 | -$0.12 | -$0.12 | +0.0% | $0.01B | $0.01B | -1.2% |
| ▲ Q1 FY2024 | Mar 18, 2024 | -$0.10 | -$0.09 | +10.0% | $0.01B | $0.01B | -5.0% |
| ▲ Q4 FY2023 | Nov 6, 2023 | -$0.12 | -$0.10 | +16.7% | $0.01B | $0.01B | -5.1% |
| ▲ Q3 FY2023 | Aug 7, 2023 | -$0.13 | -$0.12 | +7.7% | $0.01B | $0.01B | +3.9% |
| ▲ Q2 FY2023 | May 12, 2023 | -$0.15 | -$0.14 | +6.7% | $0.01B | $0.01B | +2.5% |
| — Q1 FY2023 | Mar 27, 2023 | -$0.15 | -$0.15 | +0.0% | $0.01B | $0.01B | -23.4% |
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
-$0.10
EPS Est.
-$0.15
EPS Surpr.
+33.3%
Revenue
—
Q3 FY2024
Aug 12, 2024Miss
EPS Actual
-$0.16
EPS Est.
-$0.12
EPS Surpr.
-33.3%
Revenue
$0.01B
Q2 FY2024
May 13, 2024
EPS Actual
-$0.12
EPS Est.
-$0.12
EPS Surpr.
+0.0%
Revenue
$0.01B
Q1 FY2024
Mar 18, 2024Beat
EPS Actual
-$0.09
EPS Est.
-$0.10
EPS Surpr.
+10.0%
Revenue
$0.01B
Q4 FY2023
Nov 6, 2023Beat
EPS Actual
-$0.10
EPS Est.
-$0.12
EPS Surpr.
+16.7%
Revenue
$0.01B
Q3 FY2023
Aug 7, 2023Beat
EPS Actual
-$0.12
EPS Est.
-$0.13
EPS Surpr.
+7.7%
Revenue
$0.01B
Q2 FY2023
May 12, 2023Beat
EPS Actual
-$0.14
EPS Est.
-$0.15
EPS Surpr.
+6.7%
Revenue
$0.01B
Q1 FY2023
Mar 27, 2023
EPS Actual
-$0.15
EPS Est.
-$0.15
EPS Surpr.
+0.0%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q3 FY2025 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q2 FY2025 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q1 FY2025 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q4 FY2024 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q3 FY2024 | $-0.14 | $-0.14 | $-0.14 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2024 | Nov 4, 2024 | +33.3% | $2.35 | — | — |
| ▼ Q3 FY2024 | Aug 12, 2024 | -33.3% | $2.27 | $2.27 | +0.00% |
| ▲ Q2 FY2024 | May 13, 2024 | +0.0% | $2.23 | $2.34 | +4.93% |
| ▲ Q1 FY2024 | Mar 18, 2024 | +10.0% | $3.20 | $3.33 | +4.06% |
| ▲ Q4 FY2023 | Nov 6, 2023 | +16.7% | $4.87 | $4.55 | -6.57% |
| ▲ Q3 FY2023 | Aug 7, 2023 | +7.7% | $4.02 | $4.07 | +1.24% |
| ▲ Q2 FY2023 | May 12, 2023 | +6.7% | $3.97 | $3.21 | -19.14% |
| ▲ Q1 FY2023 | Mar 27, 2023 | +0.0% | $1.50 | $1.72 | +14.67% |
Q4 FY2024—
Report Date
Nov 4, 2024
EPS Beat/Miss
+33.3%
Price Before
$2.35
Price After
—
Q3 FY2024+0.00%
Report Date
Aug 12, 2024
EPS Beat/Miss
-33.3%
Price Before
$2.27
Price After
$2.27
Q2 FY2024+4.93%
Report Date
May 13, 2024
EPS Beat/Miss
+0.0%
Price Before
$2.23
Price After
$2.34
Q1 FY2024+4.06%
Report Date
Mar 18, 2024
EPS Beat/Miss
+10.0%
Price Before
$3.20
Price After
$3.33
Q4 FY2023-6.57%
Report Date
Nov 6, 2023
EPS Beat/Miss
+16.7%
Price Before
$4.87
Price After
$4.55
Q3 FY2023+1.24%
Report Date
Aug 7, 2023
EPS Beat/Miss
+7.7%
Price Before
$4.02
Price After
$4.07
Q2 FY2023-19.14%
Report Date
May 12, 2023
EPS Beat/Miss
+6.7%
Price Before
$3.97
Price After
$3.21
Q1 FY2023+14.67%
Report Date
Mar 27, 2023
EPS Beat/Miss
+0.0%
Price Before
$1.50
Price After
$1.72
Avg Beat Reaction-0.14%
Avg Miss Reaction+0.00%
Beat Rate7 / 8 quarters
Largest Move-19.14% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AUGX ends December
Augmedix, Inc. (AUGX) most recently reported earnings on November 4, 2024 for Q4 FY2024, posting EPS of $-0.10 — beating the analyst consensus of $-0.15 by +33.3%. The next AUGX earnings date is expected around September 1, 2026.
Each quarter, investors track AUGX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AUGX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AUGX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AUGX earnings · 5 questionsAugmedix, Inc.'s next earnings report is expected around September 1, 2026. AUGX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AUGX historically reports after market close (AMC).
AUGX earnings datewhen is AUGX earningsAUGX next earnings datewhen does AUGX report earningsAUGX earnings calendar
▸ Source: FMP · Augmedix, Inc. SEC filings · US GAAP · Augmedix, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026